PURPOSE: To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL). PATIENTS AND METHODS: Immunocompetent patients (18 to 60 years of age) with untreated PCNSL were randomly assigned to receive WBRT or ASCT as consolidation treatment after induction chemotherapy consisting of two cycles of R-MBVP (rituximab 375 mg/m2 day (D) 1, methotrexate 3 g/m2 D1; D15, VP16 100 mg/m2 D2, BCNU 100 mg/m2 D3, prednisone 60 mg/kg/d D1-D5) followed by two cycles of R-AraC (rituximab 375 mg/m2 D1, cytarabine 3 g/m2 D1 to D2). Intensive chemotherapy consisted of thiotepa (250 mg/m2/d D9; D8; D7), busulfan (8 mg/kg D6 through D4), and cyclophosphamide (60 mg/kg/d D3; D2). WBRT delivered 40 Gy (2 Gy/fraction). The primary end point was 2-year progression-free survival. Cognitive outcome was the main secondary end point. Analysis was intention to treat in a noncomparative phase II trial. RESULTS:Between October 2008 and February 2014, 140 patients were recruited from 23 French centers. Both WBRT and ASCT met the predetermined threshold (among the first 38 patients in each group, at least 24 patients were alive and disease free at 2 years). The 2-year progression-free survival rates were 63% (95% CI, 49% to 81%) and 87% (95% CI, 77% to 98%) in the WBRT and ASCT arms, respectively. Toxicity deaths were recorded in one and five patients after WBRT and ASCT, respectively. Cognitive impairment was observed after WBRT, whereas cognitive functions were preserved or improved after ASCT. CONCLUSION:WBRT and ASCT are effective consolidation treatments for patients with PCNSL who are 60 years of age and younger. The efficacy end points tended to favor the ASCT arm. The specific risk of each procedure should be considered.
RCT Entities:
PURPOSE: To determine the efficacy and toxicity of chemoimmunotherapy followed by either whole-brain radiotherapy (WBRT) or intensive chemotherapy and autologous stem-cell transplantation (ASCT) as a first-line treatment of primary CNS lymphoma (PCNSL). PATIENTS AND METHODS: Immunocompetent patients (18 to 60 years of age) with untreated PCNSL were randomly assigned to receive WBRT or ASCT as consolidation treatment after induction chemotherapy consisting of two cycles of R-MBVP (rituximab 375 mg/m2 day (D) 1, methotrexate 3 g/m2 D1; D15, VP16 100 mg/m2 D2, BCNU 100 mg/m2 D3, prednisone 60 mg/kg/d D1-D5) followed by two cycles of R-AraC (rituximab 375 mg/m2 D1, cytarabine 3 g/m2 D1 to D2). Intensive chemotherapy consisted of thiotepa (250 mg/m2/d D9; D8; D7), busulfan (8 mg/kg D6 through D4), and cyclophosphamide (60 mg/kg/d D3; D2). WBRT delivered 40 Gy (2 Gy/fraction). The primary end point was 2-year progression-free survival. Cognitive outcome was the main secondary end point. Analysis was intention to treat in a noncomparative phase II trial. RESULTS: Between October 2008 and February 2014, 140 patients were recruited from 23 French centers. Both WBRT and ASCT met the predetermined threshold (among the first 38 patients in each group, at least 24 patients were alive and disease free at 2 years). The 2-year progression-free survival rates were 63% (95% CI, 49% to 81%) and 87% (95% CI, 77% to 98%) in the WBRT and ASCT arms, respectively. Toxicity deaths were recorded in one and five patients after WBRT and ASCT, respectively. Cognitive impairment was observed after WBRT, whereas cognitive functions were preserved or improved after ASCT. CONCLUSION: WBRT and ASCT are effective consolidation treatments for patients with PCNSL who are 60 years of age and younger. The efficacy end points tended to favor the ASCT arm. The specific risk of each procedure should be considered.
Authors: R Velasco; S Mercadal; F Graus; N Vidal; M Alañá; M I Barceló; M J Ibáñez-Juliá; S Bobillo; R Caldú Agud; E García Molina; P Martínez; P Cacabelos; A Muntañola; G García-Catalán; J M Sancho; I Camro; T Lado; M E Erro; L Gómez-Vicente; A Salar; A C Caballero; M Solé-Rodríguez; J Gállego Pérez-Larraya; N Huertas; J Estela; M Barón; N Barbero-Bordallo; M Encuentra; I Dlouhy; J Bruna Journal: J Neurooncol Date: 2020-06-10 Impact factor: 4.130
Authors: Thomas Mika; Swetlana Ladigan; Alexander Baraniskin; Deepak Vangala; Sabine Seidel; Olaf Hopfer; Michael Kiehl; Roland Schroers Journal: Haematologica Date: 2019-08-08 Impact factor: 9.941
Authors: Huimin Geng; Mazie Tsang; Lakshmipriya Subbaraj; Joseph Cleveland; Lingjing Chen; Ming Lu; Jigyasa Sharma; Daniel B Vigneron; John Kurhanewicz; Marisa LaFontaine; Tracy Luks; Bruce A Barshop; Jon Gangoiti; Javier E Villanueva-Meyer; James L Rubenstein Journal: Neuro Oncol Date: 2021-10-01 Impact factor: 12.300
Authors: Michael Scordo; Trent P Wang; Kwang W Ahn; Yue Chen; Sairah Ahmed; Farrukh T Awan; Amer Beitinjaneh; Andy Chen; Victor A Chow; Bhagirathbhai Dholaria; Narendranath Epperla; Umar Farooq; Nilanjan Ghosh; Natalie Grover; Nada Hamad; Gerhard C Hildebrandt; Leona Holmberg; Sanghee Hong; David J Inwards; Antonio Jimenez-Jimenez; Reem Karmali; Vaishalee P Kenkre; Farhad Khimani; Evgeny Klyuchnikov; Maxwell M Krem; Pashna N Munshi; Yago Nieto; Tim Prestidge; Praveen Ramakrishnan Geethakumari; Andrew R Rezvani; Peter A Riedell; Sachiko Seo; Nirav N Shah; Melhem Solh; Jean A Yared; Mohamed A Kharfan-Dabaja; Alex Herrera; Mehdi Hamadani; Craig S Sauter Journal: JAMA Oncol Date: 2021-07-01 Impact factor: 31.777
Authors: Arushi Khurana; Mattia Novo; Grzegorz S Nowakowski; Kay M Ristow; Robert J Spinner; Christopher H Hunt; Rebecca L King; Daniel H Lachance; Thomas M Habermann; Ivana N Micallef; Patrick B Johnston Journal: Blood Adv Date: 2021-03-09